A Phase 1 interventional study of [¹⁴C]Enlicitide chloride in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to male participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-26.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to learn what happens to enlicitide chloride labeled with [¹⁴C] in a person's body over time. A label can be added to a study medicine to trace it in a person's body.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single dose of \[¹⁴C\]enlicitide chloride on Day 1.
Drug: [¹⁴C]Enlicitide chloride
IV Injection
Also known as: MK-0616
Cumulative Amount of Radioactivity Excreted in Urine (Aeu)
Urine samples will be collected to determine the Aeu of \[¹⁴C\]enlicitide chloride.
Time frame: At designated timepoints (up to 15 days)
Cumulative Amount of Radioactivity Excreted in Feces (Aef)
Fecal samples will be collected to determine the Aef of \[¹⁴C\]enlicitide chloride.
Time frame: At designated timepoints (up to 15 days)
Cumulative Percentage of Radioactivity Excreted in Urine (feu)
Urine samples will be collected to determine the feu of \[¹⁴C\]enlicitide chloride.
Time frame: At designated timepoints (up to 15 days)
Cumulative Percentage of Radioactivity Excreted in Feces (fef)
Fecal samples will be collected to determine the fef of \[¹⁴C\]enlicitide chloride.
Time frame: At designated timepoints (up to 15 days)
Plasma Enlicitide Chloride: Area Under the Concentration-Time Curve from Time 0 to the Last Measurable Concentration (AUC0-t)
Plasma samples will be collected to determine the AUC0-t of enlicitide chloride.
Time frame: At designated timepoints (up to 15 days)
Plasma Enlicitide Chloride: Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-inf)
Plasma samples will be collected to determine the AUC0-inf of enlicitide chloride.
Time frame: At designated timepoints (up to 15 days)
Plasma Enlicitide Chloride: Maximum Plasma Concentration (Cmax)
Plasma samples will be collected to determine the Cmax of enlicitide chloride.
Time frame: At designated timepoints (up to 15 days)
Plasma Enlicitide Chloride: Apparent Terminal Half-life (t1/2)
Plasma samples will be collected to determine the t1/2 of enlicitide chloride.
Time frame: At designated timepoints (up to 15 days)
Plasma Enlicitide Chloride: Time to Maximum Plasma Concentration (Tmax)
Plasma samples will be collected to determine the Tmax of enlicitide chloride.
Time frame: At designated timepoints (up to 15 days)
Plasma Total Reactivity: AUC0-t
Plasma samples will be collected to determine the AUC0-t of total reactivity.
Time frame: At designated timepoints (up to 15 days)
Plasma Total Reactivity: AUC0-inf
Plasma samples will be collected to determine the AUC0-inf of total reactivity.
Time frame: At designated timepoints (up to 15 days)
Plasma Total Reactivity: Cmax
Plasma samples will be collected to determine the Cmax of total reactivity.
Time frame: At designated timepoints (up to 15 days)
Plasma Total Reactivity: t1/2
Plasma samples will be collected to determine the t1/2 of total reactivity.
Time frame: At designated timepoints (up to 15 days)
Plasma Total Reactivity: Tmax
Plasma samples will be collected to determine the Tmax of total reactivity.
Time frame: At designated timepoints (up to 15 days)
Enlicitide Chloride to Total Radioactivity Ratio of Area Under the Concentration-Time Curve from Time 0 to the Last Detectable Sample (enlicitide chloride AUC0-x/total radioactivity AUC0-x)
Plasma samples will be collected to determine the enlicitide chloride AUC0-x/total radioactivity AUC0-x.
Time frame: At designated timepoints (up to 15 days)
Number of Participants Who Experience an Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not considered related to the study intervention.
Time frame: Up to approximately 29 days
Number of Participants Who Discontinue the Study Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not considered related to the study intervention.
Time frame: Up to approximately 29 days
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Mar 2023 to primary completion in Aug 2023, 4 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enlicitide chloride